NewAmsterdam Pharma Files 8-K
Ticker: NAMSW · Form: 8-K · Filed: Jun 9, 2025 · CIK: 1936258
Sentiment: neutral
Topics: 8-K, financial-statements, regulatory-filing
TL;DR
NAP filed an 8-K on 6/9/25, mostly financial statements and exhibits.
AI Summary
On June 9, 2025, NewAmsterdam Pharma Company N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates that NewAmsterdam Pharma is providing updated financial information and potentially disclosing other material events to the SEC, which is important for investors to monitor.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting routine financial statements and exhibits, with no immediate indication of significant new risks or material adverse events.
Key Players & Entities
- NewAmsterdam Pharma Company N.V. (company) — Registrant
- June 9, 2025 (date) — Date of earliest event reported
FAQ
What specific financial statements or exhibits are included in this 8-K filing?
The provided excerpt states that the filing includes 'Financial Statements and Exhibits' but does not detail the specific documents.
What 'Other Events' are being reported by NewAmsterdam Pharma?
The excerpt lists 'Other Events' as an item information category but does not specify what those events are.
What is the purpose of the Regulation FD Disclosure mentioned in the filing?
The filing indicates a 'Regulation FD Disclosure' but does not provide details on the specific information being disclosed under this regulation.
When was NewAmsterdam Pharma Company N.V. incorporated or registered?
The filing states the company's jurisdiction of incorporation is 'The Netherlands' but does not provide a specific incorporation date.
What is the principal executive office address for NewAmsterdam Pharma?
The principal executive offices are located at Gooimeer 2-35, Naarden, The Netherlands, 1411 DC.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 9, 2025 regarding NewAmsterdam Pharma Co N.V. (NAMSW).